Company Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. is headquartered in Mississauga, Canada.
| Country | Canada |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Arun Menawat |
Contact Details
Address: 2400 Skymark Avenue, Unit 6 Mississauga, ON L4W 5K5 Canada | |
| Phone | 647 476 1350 |
| Website | profoundmedical.com |
Stock Details
| Ticker Symbol | PROF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001628808 |
| CUSIP Number | 74319B502 |
| ISIN Number | CA74319B5027 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arun Swarup Menawat MBA, Ph.D. | Chairman of the Board and Chief Executive Officer |
| Stephen Kilmer | Investor Relations |
| Thomas Tamberrino MBA | Chief Commercial Officer |
| Matthew Sobczyk C.A., CPA | Assistant Corporate Controller |
| Levant Tinaz | Software Developer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 7, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Oct 17, 2024 | 6-K | Report of foreign issuer |
| Oct 16, 2024 | 6-K | Report of foreign issuer |
| Oct 11, 2024 | SCHEDULE 13G/A | Filing |
| Sep 23, 2024 | 144 | Filing |
| Sep 23, 2024 | 144 | Filing |